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prior to treatment initiation. Multinomial logistic regression
models were used to estimate the probability of treatment 
with olanzapine, quetiapine, or risperidone (reference group)
monotherapy based on patients’ demographic, clinical charac-
teristics and health care resource utilization during the three
months prior to treatment initiation. RESULTS: A total of 838
patients (mean age 38.9 [SD: 11.4] years) met inclusion criteria.
Patients were initiated on monotherapy with either olanzapine
(n = 393), risperidone (n = 262), or quetiapine (n = 183). Com-
pared to risperidone, patients aged 25–34, and 55–64 years were
more likely than other age groups to receive olanzapine. African-
American patients were less likely to initiate olanzapine or que-
tiapine. Women were more likely than men to receive quetiapine,
compared with risperidone. Patients whose ﬁrst bipolar episode
was depressive or who had used second generation antidepres-
sants during the three-month baseline period were less likely to
initiate olanzapine. Patients who used second generation antide-
pressants were more likely to receive quetiapine than risperidone.
Patients in the two counties with the largest population of
patients diagnosed with bipolar disorder were less likely to 
initiate quetiapine. CONCLUSIONS: Several variables, includ-
ing gender, race, type of ﬁrst bipolar episode, and county of res-
idence were associated with the choice of atypical antipsychotic
monotherapy used to treat bipolar disorder.
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OBJECTIVES: This study aims to evaluate the impact of Atten-
tion Deﬁcit Hyperactivity Disorder (ADHD) Narcolepsy Clini-
cal Prior Authorization program on prescription drug utilization
and costs. METHODS: Using pre-post with control group
approach, prescription records from April 2003 to June 2005
were obtained from pharmacy claims database in a pharmacy
beneﬁt management organization. The study group comprised of
eight clients enrolled in ADHD Narcolepsy program, while the
control group comprised of all other clients not enrolled in this
program. Number of prescriptions dispensed per month per
thousand eligible members, and per member per month (PMPM)
total, plan and member costs were analyzed and compared.
PMPM cost savings were calculated using the following formula:
Y¢ = Yst0*Rct - Yst1 where Yst0 and Yst1 represent actual pre and
post PMPM costs in the study group and Rct is the ratio of
PMPM post and pre costs in the control group. RESULTS: The
study group included 60,916 eligible lives from eight clients, and
the control group included 526,612 lives from 109 clients. From
the pre to post period, in the study group, the average number
of prescriptions per month per thousand eligible lives and the
average PMPM total costs decreased by 35% (from 7.38 to 4.82)
and 24% (from $0.68 to $0.51) respectively. In the control
group, however, the average number of prescriptions and the
average PMPM costs increased by 40% (from 5.18 to 7.25) and
68% (from $0.47 to $0.79). After comparing the trend in these
two groups, ADHD Narcolepsy Clinical Prior Authorization was
estimated to result in $0.63 PMPM and $460,525 annualized
cost savings for the eight clients as a whole. CONCLUSION:
ADHD Narcolepsy Clinical Prior Authorization program led to
decrease of prescription utilization and savings in PMPM costs
and was an effective strategy in controlling prescription drug 
utilization and costs.
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OBJECTIVES: This study evaluated the impact of Selective 
Serotonin Reputake Inhibitor (SSRI) Step Care program on 
prescription drug utilization and expenditures. METHODS:
Using pre-post with control group study approach, prescription
records from October 2003 to April 2005 were obtained from
pharmacy claims database in a pharmacy beneﬁt management
organization. The study group comprised of patients enrolled in
SSRI Step Care, while the control group comprised of those not
enrolled in this program. Number of prescriptions dispensed and
total costs per member per month (PMPM) for both targeted
brand drugs and shift-to-generic drugs were compared between
the study and control groups. RESULTS: The study group
included 62,451 eligible lives, and the control group included
341,971 lives. From the pre to post period, in the study group,
the average number of prescriptions per month per thousand eli-
gible lives and the average PMPM total costs decreased by
37.5% (from 26 to 16.26) and 31.3% (from $2.25 to $1.54) for
the target drugs, and increased by 48% (from 11.7 to 17.3) and
15.4% (from $0.79 to $0.91) for the shift-to-drugs respectively.
In the control group, however, the average number of prescrip-
tions and the average PMPM costs increased by 18.3% (from
21.18 to 17.31) and 13.4% (from $1.95 to $1.69) for the target
drugs, decreased by 8.6% (from 10.4 to 9.5) and 25% (from
$0.82 to $0.62) for the shift-to-drugs. SSRI Step Care was esti-
mated to result in $0.41 PMPM cost savings in the target drugs
but $0.31 PMPM cost increase in the shift-to-drugs, and a net
PMPM total cost savings of $0.10. CONCLUSIONS: SSRI Step
Care was found to shift prescription drug utilization from expen-
sive brand names to low cost generics. A medication manage-
ment program such as SSRI Step Care has been shown to lower
prescription drug expenditures.
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OBJECTIVES: To evaluate the likelihood of employment termi-
nation among patients with bipolar disorder (BPD) treated with
different classes of psychotropic medications. METHODS:
Patients with BPD (classiﬁed according to ICD-9-CM codes)
were identiﬁed from the Human Capital Management Services
Research Reference Database. Patients with continuous eligibil-
ity six months before and 12 months after their initial prescrip-
tion treatment for BPD were categorized into those using:
atypical antipsychotics only (ATYP); conventional antipsy-
chotics, mood stabilizers (including lithium, divalproex, lamot-
rigine, and carbamazepine), and speciﬁc anticonvulsants only
(OTHER); medications from both categories (BOTH); and no
study-speciﬁed psychotropic medications (NONE). The index
“prescription” date for the NONE group was deﬁned as six
months after the initial diagnosis. Both voluntary and involun-
tary terminations of employment were included. Regression
models controlled for possible confounding factors (age, gender,
